Navigation Links
Baby Boomers Should Get Tested for Hepatitis C

ALEXANDRIA, Va., June 24, 2013 /PRNewswire/ -- The American Association for the Study of Liver Diseases (AASLD) applauds the US Preventive Services Task Force (USPSTF) decision of June 24, 2013 giving a "B" rating for testing baby boomers for hepatitis C virus. This seemingly small change -- from a "C" to a "B" -- in the USPSTF rating signals an incredible change in the lives of patients who have HCV and are unaware of it. A "B" rating allows for payment by Medicare and private insurers for testing with no copayment by patients.

More than 75 percent of the estimated 3 million US citizens with HCV are baby boomers. This new USPSTF "B" rating for HCV testing of baby boomers matches its rating for HCV testing among injection drug users and others at high risk.  

Earlier this year, the Centers for Disease Control and Prevention (CDC) recommended an age-based screening strategy that required a one-time test for everyone born between 1945 and 1965. The USPSTF had initially recommended a "C" rating for this birth cohort in a draft proposal, conflicting with the CDC recommendation and creating confusion in the primary care community. The change from a "C" to a "B" rating gives primary care clinicians the absolute clarity of the hepatology community -- early detection of HCV allows for the drastically greater possibility of treatment success for patients.

HCV is usually an asymptomatic disease, and three out of four of those afflicted are unaware of their infection until their liver disease is far advanced. To allow the disease to progress to the point where a patient is showing symptoms greatly increases the danger of the disease, decreases our abilities to treat these patients, and often results in the development of liver cancer, frequently requiring liver transplantation -- at best. Liver cancer is one of the few cancers increasing in frequency and has one of the highest mortality rates. The ability of a patient to be tested and treated for HCV at the earliest possible date allows him or her to avoid the disease's progression to liver cancer.

Liver transplantation is an expensive procedure and testing for HCV with subsequent treatment is expected to decrease the number of patients who would otherwise require transplantation and provides a significant financial savings to the nation's healthcare system. It is worthy of note that these recommendations come at a time when the treatments for hepatitis C are becoming both more effective and easier to tolerate.  The other savings is even greater -- decreasing the number of patients requiring and waiting for a liver transplantation equals saving lives. The number of livers available does not match the number of patients who currently require a transplantation, which means that patients die while on the waiting list. In 2012, there were 6,256 liver transplantations performed. As of June 7, 2013, there are 16,484 patients waiting for a suitable organ.

The CDC recommended one-time age-based screening allowing for early detection of HCV reduces the chance of progression to liver cancer, and decreases the number of patients requiring a liver transplantation. The new "B" rating by the USPSTF means that a large number of patients can be tested and successfully treated with new direct-acting antiviral drugs that have allowed the medical community to cure HCV. Ten years ago, we were not able to cure patients of HCV, but research in liver disease has led to these new drugs. Treatment is still difficult and expensive, but it is constantly improving, and we anticipate the FDA to approve numerous new drugs over the next three to five years. New drugs currently in the pipeline will allow us to increase the cure rate and decrease treatment side effects. 

AASLD is a subspecialty society representing clinicians and researchers in liver disease. The work of our members has laid the foundation for the development of drugs used to treat patients with HCV. Our members are on the frontline of treating and curing these patients. This decision by the USPSTF helps us help patients.

AASLD is the leading organization of scientists and healthcare professionals committed to preventing and curing liver disease. AASLD was founded in 1950 by a small group of leading liver specialists and has grown to an international society responsible for all aspects of hepatology.

Press releases and additional information about AASLD are available online at

Media Contact: Gregory Bologna

This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit

SOURCE American Association for the Study of Liver Diseases (AASLD)
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Market for Medical Imaging Equipment to Reach $25.3 Billion as Retiring Boomers and Emerging Markets Demand Better Healthcare
2. Sounds Like The Mesh Should Come Out!
3. European Orthopedic Market 2017 Forecasts: Hip, Knee & Shoulder Analysis in New Research Report at
4. Omthera Pharmaceuticals, Inc. Stockholders Seeking More Money, Information in Buyout Should Contact Deans & Lyons Law Firm
5. Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises
6. 40 percent of parents give young kids cough/cold medicine that they shouldnt
7. Physician Patient Alliance for Health & Safety: CMS Quality Measures Should Include Continuous Electronic Monitoring of Patients Using Patient-Controlled Analgesia
8. Home Affairs Committees Drugs Report: Angelus Foundation Says the Prime Minister Should Not Have Rejected a Royal Commission
9. What Men Should Know About Prostate Cancer -- But Dont
10. Cost vs. Reality - What CT Scanner Should I Choose?
11. American Journal of Obstetrics and Gynecology Publishes PeriGen Research on Shoulder Dystocia
Post Your Comments:
(Date:11/24/2015)... The uptake of recently approved and pipeline premium products for Type 1 ... 2021, says GBI Research . --> ... Diabetes Mellitus (T1DM), will be a key driver of market growth to ... The uptake of recently approved and pipeline premium products for Type ... to 2021, says GBI Research . ...
(Date:11/24/2015)... Nov. 24, 2015  Enova Illumination is pleased to ... Helsinki, Finland to combine their world ... the cutting edge of medical visualization: Enova is the ... the United States and Novocam is the ... provide the world,s most powerful battery-operated LED headlight with ...
(Date:11/24/2015)... , Nov. 24, 2015  BioPlast Manufacturing, ... the medical research, clinical diagnostic and biotech environments, ... leading manufacturer of quality petri dishes. This acquisition ... clients a platform of products that are designed ... with the highest quality.  ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... ... Dr. Todd S. Afferica, a noted general dentist in Norcross, GA ... Afferica now uses the BIOLASE WaterLase iPlus 2.0™ in many of his dental procedures. ... traditional cutting tools, such as the scalpel and high-speed drill, which can both cause ...
(Date:11/24/2015)... ... November 24, 2015 , ... In an article published November ... determine which patients are or are not eligible for bariatric surgery. The article explains ... 40, are more than 100 pounds overweight, or have a BMI of 35 and ...
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to five ... is critical that the first impression be positive and reflects business values. If a ... buy anything or want to return. They will also share their thoughts about a ...
(Date:11/24/2015)... ... 24, 2015 , ... Cancer patients, survivors, caregivers, family members ... live taping of the next CURE Connections® video series on Saturday, ... Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding from the ... study designed to yield insights into how to detect and treat pancreatic cancer (PC). ... cancer from small, non-coding RNA molecules (ncRNA), genetic material that is present in the ...
Breaking Medicine News(10 mins):